SKF-110679

Description

Overview of SKF-110679?

SKF-110679 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide. It belongs to the growth hormone secretagogue family. It was developed to study the regulation of growth hormone (GH) secretion in research models.

SKF-110679 interacts with growth hormone secretagogue receptors (GHS-R) in the hypothalamus and anterior pituitary. This receptor activity can stimulate the release of growth hormone (GH). This peptide is investigated by researchers to study endocrine signaling pathways involved in growth hormone regulation.

Chemical Properties of SKF-110679

Property	Information
CAS Number	87616-84-0
Molecular Formula	C46H56N12O6
Molecular Mass	873.0 g/mol
Synonyms	SKF-110679, GTPL1093, SCHEMBL28021776, orb341840
IUPAC Name	6-amino-2-[[2-[[2-[2-[[2-[[2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoylamino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide
Storage	2-8°C (36-46°F)

Mechanism of Action

SKF-110679 acts by binding to the growth hormone secretagogue receptor (GHS-R1a). GHS-R1a is a G-protein-coupled receptor found in the hypothalamus and the anterior pituitary. When this receptor is activated, it triggers intracellular signaling pathways. These signals include increases in intracellular calcium and activation of protein kinase pathways. As a result, somatotroph cells in the anterior pituitary of experimental models release growth hormone (GH).

SKF-110679 can also affect hypothalamic neurons that regulate the release of growth hormone-releasing hormone (GHRH). This interaction may increase GH secretion through complementary signaling pathways. Studies suggest that receptor activation can affect downstream hormonal pathways, such as changes linked with insulin-like growth factor-1 (IGF-1) signaling.

Research Findings on SKF-110679

Experimental studies have shown that SKF-110679 stimulates GH release via receptor-mediated pathways in endocrine models. Research indicates that this peptide triggers GH secretion at both hypothalamic and pituitary levels. This demonstrates SKF-110679’s role as a potent GH secretagogue in research.

Studies examining endocrine signaling pathways found that SKF-110679 can enhance GH secretion and may act synergistically with GHRH. It is reported that the combined stimulation can produce a greater GH response compared with either peptide alone. This indicates complementary regulatory pathways involved in GH release.

Where to buy SKF-110679 for research purposes?

Researchers looking for high-quality SKF-110679 can find reliable suppliers that specialize in research peptides. PureRawz offers SKF-110679 intended for laboratory and research applications. We focus on providing materials that support experimental studies and analytical work in controlled research conditions.

All our products are supplied with reference materials and an independent third-party Certificate of Analysis (COA). This documentation verifies key details such as identification, purity, and concentration.

Disclaimer

This information is for educational purposes only and not medical advice. Products are for research use only. Research must follow IRB or IACUC guidelines. Verify information independently before purchasing. By ordering, you agree to our Terms and Conditions. If you are not 100% satisfied with the product you received, please contact us at support@purerawz.co

ATTENTION: All our products are for LABORATORY AND RESEARCH PURPOSES ONLY, not for veterinary or human use

Reference Links

Lei, T, et al. 'Growth Hormone Releasing Peptide (SKF-110679) Stimulates Phosphatidylinositol (PI) Turnover in Human Pituitary Somatotroph Cells.' Journal of Molecular Endocrinology, vol. 14, no. 1, Feb. 1995, pp. 135-8, pubmed.ncbi.nlm.nih.gov/7772238/, https://doi.org/10.1677/jme.0.0140135.

Micle, D., Popovic, V., Kendereski, A., Macut, D., Casanueva, F. F., & Dieguez, C. (1995). Growth hormone secretion after the administration of SKF-110679 or GHRH combined with SKF-110679 does not decline in late adulthood. Clinical Endocrinology, 42(2), 191-194. https://doi.org/10.1111/j.1365-2265.1995.tb01861.x